Stock A144510 GC CELL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

GC Cell Corporation Stock

Equities

A144510

KR7144510005

Healthcare Facilities & Services

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
37,850 KRW -0.26% Intraday chart for GC Cell Corporation +5.87% -16.81%
Feb. 26 GC Cell and Biocentriq® Execute Process Transfer Agreement in Anticipation of the U.S. Entry of Immuncell-LC Inj CI
Jan. 08 GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform CI

Financials

Sales 2022 236B 172M Sales 2023 188B 136M Capitalization 684B 497M
Net income 2022 24.99B 18.17M Net income 2023 -174M -126K EV / Sales 2022 3.12 x
Net Debt 2022 27.67B 20.12M Net Debt 2023 78.87B 57.34M EV / Sales 2023 4.07 x
P/E ratio 2022
29.1 x
P/E ratio 2023
-3,792 x
Employees 769
Yield 2022
0.74%
Yield 2023
0.22%
Free-Float 52.38%
More Fundamentals * Assessed data

Chart GC Cell Corporation

Dynamic Chart

Latest news about GC Cell Corporation

GC Cell and Biocentriq® Execute Process Transfer Agreement in Anticipation of the U.S. Entry of Immuncell-LC Inj CI
GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform CI
GC Cell Affiliate BioCentriq Secures $29 Million in Funding Round MT
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment MT
GC Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GC Cell Obtains Anti-Bribery Management System Certification from Korea Compliance Initiative CI
GC Cell Inks First Licensing Agreement for Immuncell-LC® With Rivaara Immune Private Limited in India CI
Green Cross Lab Cell Corporation completed the acquisition of Green Cross Cell Corporation from a group of shareholders. CI
Green Cross Lab Cell Corporation entered into a definitive merger agreement to acquire Green Cross Cell Corporation from a group of shareholders for approximately KRW 510 billion. CI
Artiva Biotherapeutics, Inc. announced that it has received $120.000001 million in funding from a group of investors CI
Artiva Biotherapeutics, Inc. announced that it expects to receive $120.000001 million in funding CI
Artiva Biotherapeutics, Inc. announced that it expects to receive $80.552315 million in funding from 5AM Venture Management, LLC, venBio LLC, RA Capital Management, L.P., Medivate Partners LLC, Green Cross Holdings Corporation, Green Cross Lab Cell Corporation CI
Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell to Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy CI
Green Cross LabCell and Feldan Therapeutics Announce a Joint Research Collaboration to Develop Low Immunogenicity, High-Performance Natural Killer Anticancer Treatment CI
Green Cross Lab Cell Corporation Announces Executive Changes CI
More news

Quotes and Performance

1 day-0.26%
1 week+5.87%
Current month-9.88%
1 month-15.61%
3 months-5.73%
6 months+26.80%
Current year-16.81%
More quotes

Highs and lows

1 week
35 500.00
Extreme 35500
38 500.00
1 month
35 500.00
Extreme 35500
45 100.00
Current year
35 500.00
Extreme 35500
48 800.00
1 year
28 450.00
Extreme 28450
48 800.00
3 years
28 450.00
Extreme 28450
125 800.00
5 years
21 250.00
Extreme 21250
150 700.00
10 years
20 600.00
Extreme 20600
150 700.00
More quotes

Managers and Directors - GC Cell Corporation

Managers TitleAgeSince
James Park CEO
 Chief Executive Officer 58 23-03-27
Jong-Seong Ahn CTO
 Chief Tech/Sci/R&D Officer 59 -
Pil-Seok Seong BRD
 Director/Board Member 58 -
Members of the board TitleAgeSince
Yu-Kyeong Hwang BRD
 Director/Board Member 57 14-08-31
Ho-Won Kim BRD
 Director/Board Member 66 23-03-27
Dae-Hee Lee BRD
 Director/Board Member 55 15-06-30
More insiders

ETFs positioned on GC Cell Corporation

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.00% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ +0.68% -
More ETFs positioned on GC Cell Corporation

Quotes

Date Price Change Volume
24-04-24 37,850 -0.26% 23,423
24-04-23 37,950 +1.34% 29,437
24-04-22 37,450 +3.74% 31,762
24-04-19 36,100 -1.50% 42,461
24-04-18 36,650 +2.52% 23,133

End-of-day quote Korea S.E., April 23, 2024

More quotes

Company Profile

GC Cell Corp formerly Green Cross Lab Cell Corp is a Korea-based company principally engaged in the provision of specimen testing services. The Company operates its business through four segments. The Specimen Testing Service segment provides sample testing services, clinical trial services, and veterinary testing services. The Cell Therapy segment is engaged in cell culture and technology transfer business. The Cord Blood Storage segment is engaged in the cord blood storage business. The Other Business segment is engaged in bio-logistics business and others.
Sector
Healthcare Facilities & Services
Calendar
2024-05-09 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
GC CELL CORPORATION Stock GC Cell Corporation
-16.81% 415M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-16.65% 8.36B
RADNET, INC. Stock RadNet, Inc.
+39.98% 3.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-32.00% 2.87B
SYNLAB AG Stock SYNLAB AG
-7.71% 2.47B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-10.07% 2.24B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-13.29% 1.81B
FLEURY S.A. Stock Fleury S.A.
-19.46% 1.56B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-40.57% 1.23B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+9.70% 1.13B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. A144510 Stock